$GILD — ADD 📊

$GILD — ADD 📊 Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internati 🎯 Q1 FY26 | Rev $7B | EPS $2.03 vs $1.91 🟢 | Margin 37.2% 💡 Consensus estimates for Q2 ($1.78) reflect seasonal patterns but may not fully incorporate the guidance raise and recent margin improvement. The market prices Gilead like a no-growth pharma, ignoring pipeline optionality and steady execution that could drive a multiple re-rating from ~14x to 16x forward earnings. 📉 Reward/Risk: 2.1:1 🏢 Business Quality: 7/10 - Diversified biopharma with strong HIV cash flows, growing oncology, and consistent capital returns, but facing mid-term patent cliff risks. Also in play: $AMGN $BIIB $REGN $VRTX $GILD $CTLT

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internati